Energenesis Biomedical CO.,LTD. (TPE:6657)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
44.80
-0.60 (-1.32%)
Jan 22, 2026, 10:13 AM CST
-10.93%
Market Cap4.03B
Revenue (ttm)7.46M
Net Income (ttm)-243.50M
Shares Out88.66M
EPS (ttm)-2.85
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume145,167
Average Volume310,790
Open46.15
Previous Close45.40
Day's Range44.50 - 46.25
52-Week Range39.75 - 85.60
Beta0.34
RSI60.92
Earnings DateFeb 26, 2026

About TPE:6657

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERG... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 35
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6657
Full Company Profile

Financial Performance

In 2024, TPE:6657's revenue was 7.75 million, an increase of 8.26% compared to the previous year's 7.16 million. Losses were -231.08 million, -11.25% less than in 2023.

Financial Statements